Compare ARK Genomic Revolution ETF (ARKG) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Gap Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.41, while Gap Inc trades at $21 (market cap $7.74B). The key difference: Gap Inc pays a 3.25% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Gap Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | GAP | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.31 | $29.13 |
52-Week Low | $23.38 | $18.35 |
Market Cap | — | $7.74B |
Enterprise Value | — | $10.82B |
Dividend Yield | — | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
Gap trades at $20.47, down 0.24% on the day, with a bullish technical signal supported by strong momentum indicators. The stock shows attractive valuation metrics, including a P/E of 8.12 and P/S of 0.51, while recent earnings have generally beaten expectations. Operating cash flow remains robust at $1.49 billion for 2025, and the company continues its digital transformation with AI initiatives.
The outlook is positive with a consensus price target of $26.64, implying 30% upside. Risks include competitive pressures and ongoing investigations by Pomerantz Law Firm. Analyst sentiment is mixed but leans bullish, with 39.58% recommending buy. The stock presents a value opportunity if turnaround efforts sustain momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
